This is a distressed bridge loan with a 7-week maturity, the company must either repay, refinance, or face default by mid-October. The secured position of SRX (first lien on all subsidiary IP and stock) means unsecured creditors and equity holders are structurally subordinated. Monitor for any subsequent financing, restructuring, or going-concern disclosure before the October 15 maturity date. The elimination of conversion features from the prior notes removes a potential equity-linked upside for noteholders, increasing the likelihood of a distressed outcome.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $0.0120entry
- T+1 · 3mo ago +31.67%α +31.22% · $0.0158
- T+5 · 2mo ago −8.33%α −8.41% · $0.0110
- T+20 · 7w ago −12.50%α −13.68% · $0.0105
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
How similar events traded
Executive Summary
CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior unsecured debt into a new senior secured promissory note and securing up to $6M in additional advances (total facility up to $11.67M). The company received an initial $775,665 advance (net $725,665 after legal fees) for working capital. The note matures October 15, 2026, bears 10% interest (24.99% default rate), and is secured by a pledge of 100% of the subsidiary's stock and substantially all subsidiary assets including key IP for CER-1236. The subsidiary also provided an unconditional guaranty. This is a distressed financing with a very short maturity, signaling acute liquidity needs and high refinancing risk.
Key Financial Metrics
Key Facts
- Consolidated $5,666,108.77 of prior unsecured debt into a single senior secured note with SRX Global.
- New facility provides up to $6,000,000 in additional advances, with an initial $775,665 advance funded on August 27, 2026.
- Maturity date is October 15, 2026, only ~7 weeks from the filing date, with SRX holding unilateral extension rights for up to four 30-day periods.
- Interest rate is 10% per annum, escalating to 24.99% upon an Event of Default.
- Collateral includes 100% of the subsidiary's stock (via Pledge Agreement) and substantially all subsidiary assets including key CER-1236 patents and IP (via Asset Security Agreement).
- The subsidiary (CERo Therapeutics, Inc.) provided an absolute, unconditional guaranty of payment.
- Proceeds are for paying outstanding trade payables and working capital, no growth or pipeline funding.
- The company cannot prepay the note without SRX's consent except in a change-of-control transaction.
- Previous convertible notes (from Keystone Capital Partners and SRX) were terminated and replaced, eliminating conversion features.
Financial Impact
Up to $11.67M in total secured debt, with $5.67M already outstanding and $775,665 new cash (net $725,665). Very short maturity (Oct 15, 2026) creates acute refinancing risk.
Risk Factors
- Inability to repay or refinance the $5.67M+ by October 15, 2026, triggering default and potential loss of all subsidiary assets to SRX.
- Very short maturity (7 weeks) with no committed refinancing, extreme liquidity risk.
- Secured position of SRX over all key IP (CER-1236 patents) means equity holders could be wiped out in a default scenario.
- Negative covenants restrict additional indebtedness and liens, limiting financing alternatives.
- The company is trading on OTC with no analyst coverage and 0% bullish consensus, limited access to capital markets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-095776 |
| Document: ea030403701ex10-2.htm | 0001213900-26-095776 |
| Document: ea030403701ex10-3.htm | 0001213900-26-095776 |
| Document: ea0304037-8k_cero.htm | 0001213900-26-095776 |
| Document: ea030403701ex10-4.htm | 0001213900-26-095776 |
| Document: 0001213900-26-095776-index-headers.html | 0001213900-26-095776 |
| Document: 0001213900-26-095776-index.html | 0001213900-26-095776 |
| Document: 0001213900-26-095776.txt | 0001213900-26-095776 |
Track record
5 reports on CERO
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +65.71% at T+60 after the Mar 11, 2026 report. 3 of 4 went positive at some point.
Filters
- Oct 7, 20265w ago 8-K Bearish 6/10 Entry $0.0951 Now $0.005000 +94.74% No price data
- Aug 31, 202611w ago 8-K Bearish 7/10 Viewing Entry $0.0120 to $0.0105 Now $0.005000 +58.33% ▲ +12.50% +13.68% vs SPY
- Jul 13, 202618w ago 25-NSE Bearish 7/10 Entry $0.0150 to $0.0100 Now $0.005000 +66.67% ▲ +33.33% +36.52% vs SPY
- Jun 26, 202620w ago 8-K Bearish 6/10 Entry $0.0110 to $0.009700 Now $0.005000 +54.55% ▲ +11.82% +11.56% vs SPY
- Mar 11, 202635w ago 8-K Bearish 7/10 Entry $0.0350 to $0.0340 Now $0.005000 +85.71% ▲ +2.86% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers